Scynexis INC
At a glance
EmployeesNot reported
In business sinceNot reported
HeadquartersJersey City, NJ
US patents18
SAM.gov UEIH6PSJYEW3DT9
CAGE code33SU8
Incorporated inDE
LEI529900XBHFGMNTU70154
- rare diseases
- fungal infections
- AMPK activators
- SCY-770
- antifungal triterpenoids
- SCY-247
- autosomal dominant polycystic kidney disease
- lives
Named on the company’s own website, read JUL 29, 2026
CareersCareers page — seen SEP 8, 2026
Supplier designations
For Profit Organization
Self-certified by the company in its SAM.gov registration
Patents
18 US patents granted 2004–2022, 3 of them in the five years to SEP 2025.
Pharmaceuticals 13Organic fine chemistry 4Measurement 1
- Antifungal agents with enhanced activity in acidic pHUS 11,534,433 · granted DEC 27, 2022
- Antifungal agents used in combinationUS 11,110,102 · granted SEP 7, 2021
- Salts and polymorphs of SCY-078US 10,927,142 · granted FEB 23, 2021
- Salts and polymorphs of SCY-078US 10,370,406 · granted AUG 6, 2019
- Salts and polymorphs of SCY-078US 10,174,074 · granted JAN 8, 2019
Newest 5 shown · Granted to Scynexis, Inc. · PatentsView (USPTO), data through SEP 30, 2025 · CC BY 4.0
Their plant
| Facility | City | State | Employees | Status |
|---|---|---|---|---|
| Scynexis INC | Jersey City | NJ | — | ACTIVE |
Compiled from federal records — EPA, OSHA, SAM.gov and the U.S. Census — and from the company’s own website. Federal source data is public domain. Each plant’s page names the source of every field.